Quasiexperimental Study of the Effects of Antibiotic Use, Gastric Acid-Suppressive Agents, and Infection Control Practices on the Incidence of Clostridium difficile-Associated Diarrhea in Hospitalized Patients

被引:45
作者
Aldeyab, Mamoon A. [1 ]
Harbarth, Stephan [2 ]
Vernaz, Nathalie [3 ]
Kearney, Mary P. [4 ]
Scott, Michael G. [4 ]
Funston, Chris [4 ]
Savage, Karen [4 ]
Kelly, Denise [5 ]
Aldiab, Motasem A. [6 ]
McElnay, James C. [1 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Clin & Practice Res Grp, Belfast BT9 7BL, Antrim, North Ireland
[2] Univ Geneva Hosp & Med Sch, Infect Control Program, Geneva, Switzerland
[3] Univ Geneva Hosp & Med Sch, Dept Pharm, Geneva, Switzerland
[4] United Hosp Trust, Belfast BT42 2RL, Antrim, North Ireland
[5] Whiteabbey Hosp, Newtownabbey BT37 9RH, Antrim, North Ireland
[6] German Jordanian Univ, Sch Informat & Comp, Amman 11180, Jordan
关键词
PROTON-PUMP INHIBITORS; FLUOROQUINOLONE USE; RISK-FACTORS; ANTIMICROBIAL RESISTANCE; DISEASE; EPIDEMIC; OUTBREAK; CLARITHROMYCIN; THERAPY; UPDATE;
D O I
10.1128/AAC.01214-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of this study was to evaluate the effects of antimicrobial drug use, gastric acid-suppressive agent use, and infection control practices on the incidence of Clostridium difficile-associated diarrhea (CDAD) in a 426-bed general teaching hospital in Northern Ireland. The study was retrospective and ecological in design. A multivariate autoregressive integrated moving average (time-series analysis) model was built to relate CDAD incidence with antibiotic use, gastric acid-suppressive agent use, and infection control practices within the hospital over a 5-year period (February 2002 to March 2007). The findings of this study showed that temporal variation in CDAD incidence followed temporal variations in expanded-spectrum cephalosporin use (average delay = 2 months; variation of CDAD incidence = 0.01/100 bed-days), broad-spectrum cephalosporin use (average delay = 2 months; variation of CDAD incidence = 0.02/100 bed-days), fluoroquinolone use (average delay = 3 months; variation of CDAD incidence = 0.004/100 bed-days), amoxicillin-clavulanic acid use (average delay = 1 month; variation of CDAD incidence = 0.002/100 bed-days), and macrolide use (average delay = 5 months; variation of CDAD incidence = 0.002/100 bed-days). Temporal relationships were also observed between CDAD incidence and use of histamine-2 receptor antagonists (H2RAs; average delay = 1 month; variation of CDAD incidence = 0.001/100 bed-days). The model explained 78% of the variance in the monthly incidence of CDAD. The findings of this study highlight a temporal relationship between certain classes of antibiotics, H2RAs, and CDAD incidence. The results of this research can help hospitals to set priorities for restricting the use of specific antibiotic classes, based on the size-effect of each class and the delay necessary to observe an effect.
引用
收藏
页码:2082 / 2088
页数:7
相关论文
共 35 条
[31]   Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea:: a systematic review [J].
Thomas, C ;
Stevenson, M ;
Riley, TV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (06) :1339-1350
[32]   Clostridium difficile-associated disease:: update and focus on non-antibiotic strategies [J].
Thompson, Ian .
AGE AND AGEING, 2008, 37 (01) :14-18
[33]   Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile [J].
Vernaz, Nathalie ;
Sax, Hugo ;
Pittet, Didier ;
Bonnabry, Pascal ;
Schrenzel, Jacques ;
Harbarth, Stephan .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (03) :601-607
[34]   Infection control measures to limit the spread of Clostridium difficile [J].
Vonberg, R. -P. ;
Kuijper, E. J. ;
Wilcox, M. H. ;
Barbut, F. ;
Tull, P. ;
Gastmeier, P. ;
van den Broek, P. J. ;
Colville, A. ;
Coignard, B. ;
Daha, T. ;
Debast, S. ;
Duerden, B. I. ;
van den Hof, S. ;
van der Kooi, T. ;
Maarleveld, H. J. H. ;
Nagy, E. ;
Notermans, D. W. ;
O'Driscoll, J. ;
Patel, B. ;
Stone, S. ;
Wiuff, C. .
CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :2-20
[35]  
World Health Organization Collaborating Center for Drug Statistics Methodology, 2002, GUID ATC CLASS DDDS